We serve Chemical Name:3-(3-Fluorphenyl)-3-oxopropanonitril CAS:21667-61-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(3-Fluorphenyl)-3-oxopropanonitril
CAS.NO:21667-61-8
Synonyms:Benzenepropanenitrile, 3-fluoro-β-oxo-;3-(3-Fluorphenyl)-3-oxopropanonitril;m-fluorobenzoylacetonitrile;3-Fluor-benzoylacetonitril;3-Fluorobenzoylacetonitrile;MFCD02260777;3-(3-Fluorophenyl)-3-oxopropanenitrile
Molecular Formula:C9H6FNO
Molecular Weight:163.148
HS Code:2926909090
Physical and Chemical Properties:
Melting point:89-91ºC
Boiling point:304.4±22.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.516
PSA:40.86000
Exact Mass:163.043335
LogP:1.07
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzenepropanenitrile, 3-fluoro-β-oxo- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(3-Fluorophenyl)-3-oxopropanenitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD02260777 Use and application,3-(3-Fluorphenyl)-3-oxopropanonitril technical grade,usp/ep/jp grade.
Related News: Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs. 3-(3-Fluorphenyl)-3-oxopropanonitril manufacturer When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. 3-(3-Fluorphenyl)-3-oxopropanonitril supplier When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. 3-(3-Fluorphenyl)-3-oxopropanonitril vendor ��Administrative Measures for the Joint Review, Review and Approval of Raw Materials, Medicinal Auxiliaries and Pharmaceutical Packaging Materials and Pharmaceutical Preparations�� (Consultation Draft) issued by the State Food and Drug Administration in December 2017. Supervision departments no longer accept applications for registration of APIs, pharmaceutical excipients, and packaging materials. 3-(3-Fluorphenyl)-3-oxopropanonitril factory When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. 3-(3-Fluorphenyl)-3-oxopropanonitril supplier When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. 3-(3-Fluorphenyl)-3-oxopropanonitril vendor ��Administrative Measures for the Joint Review, Review and Approval of Raw Materials, Medicinal Auxiliaries and Pharmaceutical Packaging Materials and Pharmaceutical Preparations�� (Consultation Draft) issued by the State Food and Drug Administration in December 2017. Supervision departments no longer accept applications for registration of APIs, pharmaceutical excipients, and packaging materials. 3-(3-Fluorphenyl)-3-oxopropanonitril factory When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau.
